USPTO serial 97770271
EARLI
Reviewed by CopyMark Law Group
Status 733Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- PURATH, ANICKA S
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with EARLI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Mountain View, CA, US
Mountain View, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Connie Ellerbach
Connie Ellerbach FENWICK & WEST LLP801 CALIFORNIA STREETMOUNTAIN VIEW, CA 94041United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations and products for medical purposes for the prevention, detection, localization, and treatment of infectious viral-based, diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, gastrointestinal diseases and conditions, and toxins in the body tissue and fluids of humans and animals; Drug delivery agents in the form of tablet coatings, edible wafers, powders, tablets, and capsules that facilitate the delivery of other pharmaceutical preparations into human and animal bodies; Reagents for use in therapeutics for medical purposes; Diagnostic and therapeutic preparations for medical purposes, namely, diagnostic preparations and therapeutic pharmaceutical preparations for detecting and treating infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for detecting the presence of toxins in body tissue and fluids; medical diagnostic reagents and assays for testing of body fluids, reagents for medical use, diagnostic reagents for medical uses, enzymes for medical purposes, and diagnostic nucleotides for medical use; medical diagnostic assays for testing of body fluids, biological preparations in the nature of recombinant nucleic acid vectors, biological preparations in the nature of recombinant viral vectors, transfection agents being reagents for medical use, reagents for medical use, enzymes for medical purposes, and diagnostic nucleotides for medical purposes, and diagnostic nucleotides for medical use, all for the foregoing being for the treatment of infectious viral-based, diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, gastrointestinal diseases and conditions, and toxins in the body tissue and fluids of humans and animals; medical diagnostic assays and reagents for testing of body fluids, reagents for medical use, enzymes for medical purposes, and diagnostic nucleotides for medical use, all the forgoing for medical diagnostic and treatment purposes, namely, for use in detecting and treating infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for use in detecting the presence of toxins in body tissue and fluids and for eliminating toxins from body tissue and fluids; therapeutic diagnostic agents for medical purposes, therapeutic agents in the nature of therapeutic pharmaceuticals for the treatment of cancer, infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, respiratory diseases, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, liver and pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and therapeutic agents being therapeutic diagnostic and pharmaceutical preparations for detecting the presence of toxins in body tissue and fluid and for eliminating toxins from body tissue and fluids; therapeutic agents for medical diagnostic purposes and treatment purposes, namely, biological preparation in the nature of viral vectors and non-viral transfection agents being reagents for medical use based on linear or branched polyethyleneimines, nano-particles, lipophilic particles, peptides, micelles, dendrimers, hydrogels, synthetic or naturally derived exosomes, polymeric composition, or virus-like particles, that facilitate the delivery of a wide range of pharmaceuticals or nucleic acid sequences into human and animal bodies to detect and treat infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for eliminating toxins in body tissue and fluids | ACTIVE | — |
| 009 | Scientific apparatus in the nature of medical laboratory research instruments for the detection and localization of diseases, pathogens and toxins in a biological sample obtained from humans and animals for research use | ACTIVE | — |
| 010 | Medical devices for delivering pharmaceutical preparations and genetic material into human or animal tissues and cells for the purpose of diagnosis of disease or treatment of disease, pathogens, and toxins in humans and animals, namely, syringes, implantable drug delivery pumps with and without catheters, infusion pumps, drug delivery catheters, infusion sets, cannulas, transdermal drug delivery patches, autoinjectors being injection devices for administering drugs, electroporators being electromagnetic drug delivery apparatus for medical use, and inhaled delivery devices being inhalers for medical purposes, all the forgoing sold empty and without medication; Medical devices for the delivery of pharmaceutical preparations and genetic material into human or animal tissues and cells for the purpose of diagnosis of disease or treatment of disease, pathogens, and toxins in humans and animals, namely, inhalers for medical purposes, sold empty and drug delivery patches sold without medication; Medical instruments for use in treating infectious diseases and for eliminating pathogens and toxins in humans and animals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 21, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 20, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Oct 20, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 20, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 13, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 12, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 12, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 12, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 26, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 25, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 25, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 25, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 7, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 7, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 6, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 6, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 26, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 15, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 15, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 6, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 14, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 14, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 14, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 3, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| May 3, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Feb 16, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 16, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 16, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 19, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 18, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 18, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 2, 2023 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Nov 2, 2023 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Nov 2, 2023 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 26, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 15, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 31, 2023 | NWAP | NEW APPLICATION ENTERED | — |